Kanvas Biosciences has secured an additional $12.5 million in Seed financing, co-led by DCVC and Lions Capital, to advance its pioneering work on immunotherapy. The company’s unique spatial biology platform maps the gut microbiome to identify bacterial strains that can enhance responses to immune checkpoint inhibitors (ICIs). With only 10 to 20 percent of patients responding to ICIs like Keytruda and Opdivo, Kanvas’ precision microbiome therapeutics aim to convert non-responders into responders. The newly raised funds bring Kanvas’ total Seed funding to $29.5 million and will support the advancement of drug candidates KAN-001 and KAN-003. The company plans to apply for FDA approval to begin Phase I clinical trials by 2025. By leveraging AI and data from patient samples, Kanvas aims to turn the microbiome into a druggable organ, potentially revolutionizing cancer treatment and other diseases.

Biotechnology, Healthcare, Private Equity,United States